【Diamond Investment】Announcement of Changes in Number of Shares and Fair Value of All Investment Targets, and Company's Net Asset Value per Share and Cash and Cash Equivalents Balance

1. Date of occurrence: June 5, 2026 (115/06/05) 2. Company name: Diamond Biofund Investment Co., Ltd. 3. Relationship with the company (the company or subsidiary): The company 4. Mutual shareholding ratio: Not applicable 5. Reason for occurrence: Pursuant to the letter of Taiwan Stock Exchange Corporation dated June 29, 2023 (ref. no. 1121802934), the company is required to announce monthly the changes in the number of shares and fair value of all investment targets held by the company, as well as the company's net asset value per share and cash and cash equivalents balance. 6. Countermeasures: (1) Changes in the number of shares and fair value of investment targets held by the company in May 2026 are as follows:

| Company Name | Shares Held May 2026 | Shares Held Apr 2026 | Change in Shares | Change in Fair Value (NT$'000) | | --- | --- | --- | --- | --- | | Tangible Biotech Co., Ltd. | 30,869,000 | 30,869,000 | - | 528,786 | | Yongsheng Biotech Co., Ltd. (StemCyte International Ltd.) | 32,793,150 | 26,637,150 | 6,156,000 | 102,823 | | Theia Medical Technology Co. Ltd. | 9,042,648 | 9,042,648 | - | (90) | | Xinyao Biomedical Co., Ltd. | 6,696,209 | 6,696,209 | - | 193,989 | | EyeYon Medical Ltd. | 59,018 | 59,018 | - | (1,938) | | Ditiandai Agricultural Biotechnology Co., Ltd. | 7,900,000 | 7,900,000 | - | (3,239) | | Kendall Capital Partners I, L.P | N/A | N/A | N/A | (551) | | Bilayer Therapeutics, Inc. | 915,540 | 915,540 | - | 55 | | Youyi Co., Ltd. | 5,331,428 | 5,331,428 | - | 0 | | Rejuvenate Bio Inc. | N/A | N/A | N/A | 0 | | Syncell Inc. | 10,367,059 | 10,367,059 | - | (2,073) | | Diamond No. 1 Investment Co., Ltd. | 200,000,000 | 200,000,000 | - | (7,930) | | Diamond High-Tech Investment Co., Ltd. | 200,000,000 | 200,000,000 | - | (1,043) | | **Total** | | | | **808,789** |

(2) The company's net asset value per share and cash and cash equivalents balance are as follows:

| Date | Net Asset Value per Share (NT$) | Cash and Cash Equivalents (NT$'000) | | --- | --- | --- | | May 31, 2026 | 11.85 | 2,544,831 |

7. Other matters to be stated: The company's primary investment targets are biotechnology stocks, whose share prices and fair values are significantly affected by research and development outcomes, leading to substantial fluctuations. Therefore, if the fair value changes show a decline in the current year, the company's operating revenue may become negative.